Your FREE NAPLEX Flashcards 2026 – 200+ Cards

The time for plasma concentration to fall by 50%. About 4–5 half-lives are needed to reach steady state or to effectively eliminate a drug.

A constant FRACTION of drug is eliminated per unit time; amount eliminated rises with concentration and half-life is constant. Most drugs.

A constant AMOUNT is eliminated per unit time regardless of concentration (saturated enzymes). Examples: phenytoin, ethanol, high-dose aspirin.

The fraction of an administered dose that reaches systemic circulation unchanged. IV = 100% (F = 1); oral is reduced by first-pass metabolism.

Apparent volume relating amount of drug in the body to plasma concentration. High Vd = drug distributes widely into tissues (lipophilic).

Volume of plasma cleared of drug per unit time. Determines maintenance dose. CL = dose rate ÷ steady-state concentration.

Loading dose = (Vd × target concentration) ÷ F. Used to reach therapeutic levels quickly without waiting 4–5 half-lives.

Metabolism of an oral drug by the gut wall and liver before it reaches systemic circulation, reducing bioavailability.

Pharmacokinetics = what the body does to the drug (ADME). Pharmacodynamics = what the drug does to the body (effect, receptors).

The four pharmacokinetic processes: Absorption, Distribution, Metabolism, Excretion.

The most abundant drug-metabolizing CYP enzyme. Inhibited by grapefruit, azole antifungals, and macrolides; induced by rifampin and carbamazepine.

A CYP inhibitor RAISES levels of drugs metabolized by that enzyme, increasing toxicity risk. Mnemonic inhibitors: -azoles, macrolides, grapefruit.

A CYP inducer LOWERS levels of drugs metabolized by that enzyme, risking treatment failure. Inducers: rifampin, phenytoin, carbamazepine, St. John's wort.

An inactive compound metabolized in the body to its active form. Example: clopidogrel activated by CYP2C19; codeine to morphine by CYP2D6.

CYP2C19 poor metabolizers activate less clopidogrel → reduced antiplatelet effect and higher cardiovascular risk (clopidogrel boxed warning).

Ratio of toxic dose to effective dose. A narrow TI (warfarin, digoxin, lithium, phenytoin, theophylline) requires monitoring.

An agonist binds and activates a receptor to produce an effect. An antagonist binds and blocks the receptor, producing no effect itself.

CrCl = [(140 − age) × weight kg] ÷ (72 × SCr), × 0.85 if female. Standard equation for renal drug dosing.

Standards for NONSTERILE compounding (capsules, creams, oral liquids). Sets beyond-use dates by formulation type.

Standards for STERILE compounding (IV admixtures, injections, ophthalmics). Requires ISO-classified air, garbing, and aseptic technique.

Standards for handling HAZARDOUS drugs: containment, negative-pressure rooms, and personal protective equipment to protect personnel.

The date after which a compounded preparation should not be used, based on the chapter (795/797), formulation, and storage conditions.

First in humans; small healthy-volunteer group tests SAFETY, dosing, and pharmacokinetics.

Tests EFFICACY and side effects in patients who have the target disease (larger than Phase I).

Large, randomized, often placebo-controlled trial confirming efficacy and monitoring adverse effects before FDA approval.

Post-marketing surveillance after approval to detect rare or long-term adverse effects in the general population.

The number of patients who must be treated to prevent one additional bad outcome. NNT = 1 ÷ absolute risk reduction. Lower is better.

Relative risk reduction is the proportional drop in risk; absolute risk reduction is the actual percentage-point drop. ARR drives NNT.

The probability the result occurred by chance. A p-value below 0.05 is conventionally considered statistically significant.

A range likely to contain the true value. For a ratio (RR/OR), if the 95% CI crosses 1.0 the result is not statistically significant.

Random assignment to treatment groups to balance known and unknown confounders, reducing selection bias.

Concealing group assignment. Single-blind = subjects unaware; double-blind = subjects and investigators unaware — reduces bias.

Analyzes participants in the group they were randomized to, regardless of adherence or dropout — preserves randomization and reflects real-world use.

A summarized, compiled reference (textbooks, Lexicomp, Micromedex). Best starting point for general drug information.

Original research published as a study (clinical trial, cohort). Most current but requires critical appraisal.

Relates a drug's pKa and the surrounding pH to its ionization. Weak acids are absorbed better in acidic environments; weak bases in basic.

The concentration of osmotically active particles per liter of solution (mOsm/L). Important for IV fluids and TPN tonicity.

A way to express concentration, e.g. 1:1000 means 1 g per 1000 mL (or 1 g per 1000 g). Used for epinephrine and antiseptics.

When the rate of drug in equals the rate of drug out, so concentration plateaus. Reached in about 4–5 half-lives of regular dosing.

Concentration-dependent killing with a post-antibiotic effect; often dosed once daily (extended interval). Nephro- and ototoxic — monitor levels and renal function.

Mixed kinetics where elimination is first-order at low concentrations but becomes zero-order once enzymes saturate — phenytoin is the classic example.

Highly protein-bound drugs (warfarin, phenytoin) can be displaced by another bound drug, transiently raising free (active) drug levels.

Lipophilic drugs cross membranes easily, have a high Vd, and are hepatically metabolized; hydrophilic drugs stay in plasma and are renally cleared.

Maintenance dose rate = clearance × target steady-state concentration ÷ F. Clearance, not Vd, governs the maintenance dose.

Weight-based dosing scales the dose to body weight; verify whether to use total, ideal, or adjusted body weight for the drug.

A calculation method to mix two concentrations of the same drug to get a desired intermediate strength.

The ratio of a substance's weight to the weight of an equal volume of water; converts between weight and volume in compounding.

Normal saline (0.9% NaCl) and lactated Ringer's are isotonic; matching tonicity prevents red-cell lysis or crenation.

The science of formulating and delivering drugs — dosage forms, dissolution, stability, and release mechanisms (immediate vs extended release).

An FDA mechanism to allow use of an unapproved product during a declared emergency when no adequate approved alternative exists.

Relative risk is used in cohort/RCT designs; odds ratio is used in case-control studies. Both are 'no effect' at 1.0.

Sensitivity = ability of a test to correctly identify those WITH disease; specificity = correctly identify those WITHOUT it.

Compares the cost of interventions per unit of clinical outcome (e.g., cost per life-year gained), expressed in natural units.

Measures outcomes in quality-adjusted life-years (QALYs), allowing comparison across very different therapies.

Binds and activates a receptor but produces a submaximal effect even at full occupancy (e.g., buprenorphine, varenicline).

Two products with the same rate and extent of absorption (AUC and Cmax within accepted limits); the basis for generic AB ratings.

Prescribing → Transcribing/Documenting → Dispensing → Administering → Monitoring. The pharmacist's safety role spans all five.

The FDA's strongest labeling warning, set off by a black border, highlighting serious or life-threatening risks of a drug.

Risk Evaluation and Mitigation Strategy: an FDA-required safety program (e.g., clozapine, isotretinoin) that may require prescriber/pharmacy certification or monitoring.

A biologic highly similar to a reference biologic with no clinically meaningful differences. Only an INTERCHANGEABLE biosimilar may be auto-substituted.

Dispensing an AB-rated generic that is therapeutically equivalent to the brand. Narrow-therapeutic-index drugs may need prescriber approval per state law.

High abuse potential with accepted medical use (oxycodone, fentanyl, Adderall). No refills allowed; requires a written/e-prescription.

Decreasing abuse potential. C-III to C-V may be refilled up to 5 times within 6 months if authorized.

By mouth (per os) twice a day. Common prescription abbreviations the pharmacist interprets during transcribing.

Pro re nata — as needed. The pharmacist confirms a maximum dose/frequency is specified.

Avoid 'U' (units), 'IU', 'QD/QOD', and trailing zeros (write 5 mg, not 5.0 mg) — they cause tenfold dosing errors. Use a leading zero (0.5 mg).

Avoid in significant immunocompromise and pregnancy (MMR, varicella, LAIV) because the weakened organism could cause disease.

Annual vaccination is recommended for everyone 6 months and older, ideally by the end of October each season.

Most inactivated vaccines are stored at 2–8°C (refrigerator). Never freeze them — freezing inactivates many vaccines.

The temperature-controlled storage and handling from manufacturer to administration; a break in the chain can ruin potency.

The deltoid muscle for most adult vaccines, given at a 90° angle with a 1–1.5 inch needle depending on patient size.

Hazardous drugs (many chemotherapy agents) require special containment and disposal per USP <800> and EPA rules — not the regular trash.

Patients should use DEA take-back programs or authorized collectors; pharmacies follow DEA reverse-distribution rules for expired stock.

The most serious FDA recall — reasonable probability the product will cause serious harm or death.

Insulin (unopened), many vaccines, some antibiotics after reconstitution, and certain biologics require 2–8°C storage.

Substituting a therapeutically equivalent alternative within a class per a formulary protocol (e.g., switching one PPI for another), distinct from generic substitution.

Pharmacists conserve supply, identify therapeutic alternatives, and prioritize critical patients — a tested skill under medication use and management.

Drug pairs easily confused (hydroxyzine/hydralazine). Use tall-man lettering and separation to prevent dispensing errors.

Drugs with a high risk of harm if used in error (insulin, anticoagulants, opioids, concentrated electrolytes). Require extra safeguards.

Once in use, most insulin vials/pens can be kept at room temperature for about 28 days; check the specific product labeling.

Verbal/telephone orders should be read back to confirm accuracy and documented; C-II verbal orders are limited to emergencies with a written follow-up.

A valid DEA number's check digit equals the last digit of [(sum of 1st,3rd,5th) + 2×(sum of 2nd,4th,6th)].

A C-II prescription may be partially filled, with the remainder dispensed within set time limits per federal and state rules.

C-III to C-V prescriptions may generally be transferred one time between pharmacies (or freely if pharmacies share a real-time database).

FDA-required patient handout for drugs with serious risks (e.g., NSAIDs, antidepressants); must be given with each dispense.

Capitalizing distinguishing letters of look-alike names (predniSONE vs prednisoLONE) to reduce mix-ups.

Right patient, right drug, right dose, right route, right time — the core check during dispensing and administration.

PCV (conjugate) and PPSV23 (polysaccharide) protect against pneumococcal disease; sequencing depends on age and risk per ACIP.

Recombinant zoster vaccine (Shingrix), 2 doses, recommended for adults 50+ to prevent shingles; it is not a live vaccine.

Tdap includes acellular pertussis and is given once (and each pregnancy); Td is the tetanus-diphtheria booster every 10 years.

If a vaccine is exposed outside 2–8°C, quarantine it, label 'do not use,' and contact the manufacturer/health department before discarding or using.

Many oral suspensions (e.g., amoxicillin) are stable only ~10–14 days refrigerated after reconstitution; counsel the patient on the discard date.

Use a spill kit, don PPE, contain and clean from the outside in, and dispose per USP <800> and facility policy.

Reduces GI irritation (NSAIDs, metformin, steroids) or improves absorption for some drugs; matched to the drug during dispensing.

Photosensitizing drugs (tetracyclines, fluoroquinolones, sulfonamides, amiodarone) warrant sun-protection counseling.

Allowed under DEA rules with identity proofing and two-factor authentication; now required for many C-II prescriptions.

Building the most accurate list of all a patient's medications and comparing it to new orders at every transition of care to prevent errors.

Metformin plus lifestyle change. It lowers hepatic glucose output, is weight-neutral, and does not cause hypoglycemia alone.

Hold around iodinated contrast and in significant renal impairment due to lactic-acidosis risk; common GI side effects.

Usually 2–3 (atrial fibrillation, VTE); 2.5–3.5 for certain mechanical heart valves. A rising INR raises bleeding risk.

Vitamin K for elevated INR; for serious bleeding, 4-factor prothrombin complex concentrate (PCC). FFP if PCC unavailable.

Unfractionated heparin is monitored with aPTT (or anti-Xa) and reversed with protamine sulfate.

Narrow therapeutic window; AUC/MIC ~400–600 for serious MRSA. Nephrotoxic — follow renal function closely.

Thiazide diuretic, ACE inhibitor or ARB, or calcium channel blocker. ACE/ARB preferred with diabetes or chronic kidney disease.

Dry cough, hyperkalemia, angioedema, and acute kidney injury. Contraindicated in pregnancy (teratogenic).

ARBs (-sartans) block the angiotensin II receptor and do NOT cause the cough; used when ACE inhibitors are not tolerated. Still avoid in pregnancy.

Check a baseline lipid panel; statins can rarely cause myopathy/rhabdomyolysis (muscle pain + high CK) and transaminase elevation.

Can mask hypoglycemia symptoms in diabetics, cause bradycardia, and should not be stopped abruptly (rebound). Caution in decompensated heart failure.

Nausea, visual changes (yellow-green halos), confusion, arrhythmias. Risk rises with hypokalemia. Reverse with digoxin immune Fab.

Narrow therapeutic index (~0.6–1.2 mEq/L). Levels rise with dehydration, NSAIDs, ACE inhibitors, and thiazides. Watch tremor, confusion.

Zero-order kinetics, narrow therapeutic index, many interactions; monitor levels (correct for low albumin). Causes gingival hyperplasia.

Takes 4–6 weeks for full antidepressant effect; do not stop abruptly (discontinuation syndrome); watch for serotonin syndrome with other serotonergic drugs.

Agitation, hyperreflexia, clonus, hyperthermia, and autonomic instability from excess serotonergic activity (e.g., SSRI + MAOI or tramadol).

Amiodarone inhibits warfarin metabolism, raising INR and bleeding risk — reduce the warfarin dose and monitor INR closely.

NSAIDs worsen heart failure, hypertension, chronic kidney disease, and peptic ulcer disease, and raise bleeding risk with anticoagulants.

Drug-drug, drug-food, drug-condition (disease), drug-allergy, and drug-laboratory — all screened in a prospective drug-utilization review.

N-acetylcysteine (NAC), most effective within 8 hours. Use the Rumack-Matthew nomogram to decide treatment.

Naloxone, an opioid antagonist. May need repeat dosing because its duration can be shorter than the opioid's.

Flumazenil — used cautiously because it can precipitate seizures in chronic users or mixed overdoses.

Deferoxamine, an iron chelator. Iron overdose is a leading cause of pediatric poisoning deaths.

Glucagon (for beta-blockers), high-dose insulin therapy, calcium, and IV fluids for hypotension and bradycardia.

An immune drop in platelets with paradoxical clotting after heparin. Stop all heparin and switch to a direct thrombin inhibitor (argatroban).

ACE inhibitors, ARBs, and potassium-sparing diuretics raise serum potassium; monitor K⁺ and renal function, especially together.

For healthy adults, amoxicillin or doxycycline; a macrolide where local resistance is low. Comorbidities add a respiratory fluoroquinolone or combination therapy.

Rescue = short-acting beta-agonist (albuterol) for acute symptoms. Controller = inhaled corticosteroid for daily prevention.

Rinse the mouth after use to prevent oral thrush; a spacer improves delivery; it is preventive, not a rescue inhaler.

Shake, exhale fully, seal lips, press while inhaling slowly and deeply, then hold breath ~10 seconds. A spacer improves delivery.

Take on an empty stomach, 30–60 minutes before breakfast; separate from calcium, iron, and antacids. Monitor TSH ~6–8 weeks after dose changes.

ACE inhibitors/ARBs, warfarin, isotretinoin, methotrexate, and statins are teratogenic and avoided in pregnancy.

As creatinine clearance falls, reduce the dose or extend the interval for renally cleared drugs; some are contraindicated below a CrCl threshold.

Both are nephrotoxic; aminoglycosides are also ototoxic. Monitor renal function and levels in serious infections.

Many antiarrhythmics, certain antibiotics (macrolides, fluoroquinolones), antipsychotics, and ondansetron prolong QT — additive risk increases torsades de pointes.

Dry mouth, blurred vision, constipation, urinary retention, confusion. Mnemonic: 'dry as a bone, blind as a bat, mad as a hatter.'

Reviewing refill records, patient-reported barriers (cost, side effects, beliefs), and gaps; nonadherence is a leading cause of treatment failure.

Asking the patient to restate instructions in their own words to confirm understanding — a core patient-education and health-literacy technique.

An allergy is an immune-mediated reaction (rash, anaphylaxis); an intolerance is a non-immune side effect (e.g., GI upset). Document the difference.

Cross-reactivity is low (~1–2%) and mainly with shared side chains. A true anaphylactic penicillin allergy warrants caution with cephalosporins.

Keep vitamin K intake consistent, avoid alcohol excess, report unusual bleeding, and keep INR appointments; many drugs interact.

Apixaban, rivaroxaban, dabigatran, edoxaban. No routine INR monitoring; dose-adjusted by renal function; idarucizumab reverses dabigatran, andexanet the Xa inhibitors.

For rheumatoid arthritis and psoriasis it is dosed WEEKLY; accidental daily dosing causes fatal toxicity. Supplement folic acid.

Carries a boxed warning for profound sedation, respiratory depression, and death; avoid or use the lowest doses with monitoring and naloxone.

Long-term corticosteroids must be tapered, not stopped abruptly, to avoid adrenal insufficiency from HPA-axis suppression.

Acetaminophen max ~3–4 g/day (less with liver disease/alcohol); NSAIDs risk GI bleed and kidney injury. Screen for duplications and interactions.

A potent CYP3A4 inducer; lowers levels of many drugs (oral contraceptives, warfarin, immunosuppressants) and adds serotonergic risk.

The measurable target of therapy (e.g., A1c < 7%, blood pressure < 130/80) used to evaluate effectiveness and modify the plan.

Start low and go slow; reduced renal/hepatic function and polypharmacy raise adverse-event risk. Use Beers Criteria for potentially inappropriate medications.

Doses are weight-based (mg/kg) with maximums; verify the calculation and concentration to avoid tenfold errors.

Guideline-directed therapy: an ARNI/ACE/ARB, beta-blocker, mineralocorticoid antagonist, and an SGLT2 inhibitor reduce mortality.

Use CHA2DS2-VASc to assess stroke risk; anticoagulate (DOAC or warfarin) when the score warrants it, weighing bleeding risk (HAS-BLED).

High-intensity statins (atorvastatin 40–80, rosuvastatin 20–40) for ASCVD or high risk; moderate-intensity for lower risk.

Add an SGLT2 inhibitor for kidney/heart protection, or a GLP-1 agonist for ASCVD, beyond metformin.

Give 15 g fast-acting carbohydrate, recheck glucose in 15 minutes (rule of 15s); glucagon if the patient cannot take oral.

IV fluids, IV insulin, and careful potassium repletion (insulin drives K⁺ into cells); correct the precipitating cause.

Long-acting bronchodilators (LAMA and/or LABA); inhaled corticosteroids added for frequent exacerbations or high eosinophils.

An SSRI or SNRI is first-line; allow 4–6 weeks for full effect, monitor for suicidality early, and avoid abrupt discontinuation.

Avoid tyramine-rich foods (aged cheese, cured meats) to prevent hypertensive crisis; many drug interactions.

Proton pump inhibitors are most effective; take 30–60 minutes before a meal. Long-term use risks B12, magnesium, and fracture concerns.

Start a stimulant laxative (senna) ± stool softener prophylactically; bulk-forming laxatives alone are inadequate.

Acute flare: NSAIDs, colchicine, or steroids. Chronic prevention: allopurinol or febuxostat to lower uric acid (do not start during a flare without cover).

First-line is a benzodiazepine (IV lorazepam or IM midazolam), followed by a longer-acting antiepileptic such as levetiracetam or fosphenytoin.

Low-molecular-weight heparin is preferred; warfarin and DOACs are avoided due to teratogenicity and placental crossing.

Combining increases ototoxicity and nephrotoxicity risk — monitor hearing and renal function.

Di- and trivalent cations (calcium, iron, magnesium, antacids, dairy) bind these antibiotics and block absorption — separate dosing.

Rapid IV infusion causes flushing of the upper body (vancomycin flushing/'red man' syndrome) from histamine release — slow the infusion rate.

Increases GI bleeding risk because serotonin contributes to platelet function — counsel and monitor.

CYP3A4 inhibition raises levels of simvastatin/lovastatin, increasing myopathy and rhabdomyolysis risk — hold or switch the statin.

A list of potentially inappropriate medications in older adults (e.g., certain anticholinergics, long-acting benzodiazepines) to avoid or use cautiously.

Buprenorphine (partial agonist), methadone (full agonist), and naltrexone (antagonist) are evidence-based treatments.

Warfarin's full effect takes days (factor II depletion); bridge with heparin/LMWH for acute clots until INR is therapeutic.

Hyperglycemia, weight gain, osteoporosis, infection risk, mood changes, and adrenal suppression with long-term use.

Spironolactone, eplerenone, amiloride, triamterene; raise potassium — avoid combining with ACE inhibitors/ARBs without monitoring.

Furosemide can cause hypokalemia, hypomagnesemia, dehydration, and ototoxicity at high doses; monitor electrolytes and renal function.

Enzyme-inducing antiepileptics (carbamazepine, phenytoin) lower contraceptive effectiveness — advise an alternative or backup method.

Dihydropyridines (amlodipine) act on vessels (edema, flushing); non-dihydropyridines (verapamil, diltiazem) slow the heart rate.

Rapid-acting (lispro, aspart) covers meals; long-acting (glargine, detemir, degludec) provides basal coverage. Never mix glargine with other insulins.

Glipizide, glyburide stimulate insulin release and can cause hypoglycemia and weight gain, especially in the elderly or renal impairment.

May reduce absorption if given soon after ingestion; not used for caustics, hydrocarbons, alcohols, metals, or a compromised airway.

Intramuscular epinephrine (1 mg/mL) into the anterolateral thigh is first-line; adjuncts include antihistamines, steroids, and oxygen.

Hypokalemia and hypomagnesemia worsen QT prolongation; correct electrolytes and avoid additive QT-prolonging drugs.

The FDA's voluntary reporting program for serious adverse events, product-quality problems, and medication errors for drugs, biologics, and devices.

Vaccine Adverse Event Reporting System — the program for reporting adverse events after vaccination (separate from MedWatch).

Coordinated efforts to use antibiotics only when needed, with the right drug, dose, route, and duration — slowing resistance.

Practices to reduce opioid harm: lowest effective dose, naloxone co-prescribing, PDMP checks, and patient education.

Prescription Drug Monitoring Program — a state database pharmacists check to detect duplicate or excessive controlled-substance prescriptions.

Nicotine replacement therapy, bupropion, and varenicline are first-line aids; pharmacists provide counseling and the 5 A's.

Non-medical conditions (economic stability, education, health-care access, environment, social context) that strongly shape health outcomes and adherence.

A patient's voluntary agreement to treatment after being told its nature, benefits, risks, and alternatives, given by someone with capacity.

Protects health information; share only the minimum necessary. Treatment, payment, and operations are permitted disclosures.

Respecting the patient's right to make their own informed decisions about their care.

Acting in the patient's best interest; doing good.

'Do no harm' — avoiding actions that injure the patient.

Fair, equitable treatment and allocation of resources among patients.

Pharmacists perform point-of-care screenings (blood pressure, glucose, lipids, A1c) and refer patients for follow-up — a public-health initiative.

Practicing within scope, maintaining competence, and reporting errors honestly under a non-punitive, systems-based safety culture.

The legal duty to ensure a controlled-substance prescription is for a legitimate medical purpose before dispensing it.

Pharmacists in most states can dispense naloxone under standing orders or collaborative agreements as a public-health overdose intervention.

Pharmacists must complete state-required CE hours to maintain licensure and current clinical competence.

A formal agreement letting pharmacists provide defined patient-care services (e.g., adjust therapy) under a physician's protocol.

An ADE is any harm related to medication use (including errors); an ADR is harm from a drug used appropriately.

Teach recognition of overdose, how to administer intranasal/IM naloxone, to call emergency services, and that repeat dosing may be needed.

The degree to which a person can obtain, process, and understand health information; low literacy increases nonadherence and errors.

Delivering care that respects a patient's language, beliefs, and values to improve trust, communication, and adherence.

Pharmacists must report certain events (suspected abuse, specific communicable diseases) per state law as part of public-health duty.

A pharmacist-led service reviewing a patient's full regimen to optimize outcomes — includes a comprehensive medication review and action plan.

A criteria-based, ongoing quality process that reviews how a drug is prescribed, dispensed, and monitored against best-practice standards, then drives improvement.

A structured, retrospective review after an error to find the underlying system cause — not blame an individual — and fix the process.

An ongoing, data-driven approach (e.g., Plan-Do-Study-Act cycles) to improve pharmacy processes and patient outcomes.

A PROACTIVE risk-assessment method that maps a process to find where it could fail before an error happens, then adds safeguards.

An unexpected occurrence involving death or serious harm; triggers an immediate investigation and root-cause analysis.

Scanning the drug and patient wristband to verify the 'five rights' at the point of care — a key error-prevention technology.

A managed list of preferred medications a health system or plan covers, balancing efficacy, safety, and cost; managed by the P&T committee.

A multidisciplinary group that manages the formulary, reviews drug safety, and sets medication-use policy.

How many times inventory is sold and replaced in a period. Higher turnover ties up less cash but risks shortages; managed with par levels.

The minimum stock quantity that triggers reordering, balancing stockouts against carrying cost and expiration waste.

Identify alternatives, allocate to highest-need patients, communicate with prescribers, and document — coordinated through pharmacy leadership.

Quarantine affected stock, notify patients/prescribers as needed by recall class, and arrange return per FDA and manufacturer instructions.

An experienced pharmacist who teaches, models practice, and gives feedback to students and trainees during experiential rotations.

Specific, timely, behavior-focused feedback aimed at improvement; a tested mentorship and preceptorship skill.

Assigning appropriate tasks to technicians and staff within their scope while the pharmacist retains professional responsibility.

A safety culture that distinguishes human error, at-risk behavior, and reckless conduct — supporting reporting without blame for honest mistakes.

Identifying, assessing, and reducing risks to patients and the pharmacy — from dispensing errors to regulatory and operational hazards.

Use of technology — e-prescribing, clinical decision support, automated dispensing — to improve safety and efficiency in the medication use process.

The iterative CQI cycle: plan a small change, do it, study the results, then act — adopt, adapt, or abandon — and repeat.

A quality approach focused on eliminating waste and non-value-added steps to improve efficiency and safety.

A data-driven method to reduce process variation and defects, often using the DMAIC framework.

A secure, computerized cabinet that stores and tracks medications on a unit, improving access control and inventory accuracy.

Software alerts (interaction, allergy, dose) integrated into prescribing/dispensing systems to catch errors at the point of care.

An error reaches the patient; a near miss is caught before reaching the patient. Both are reported to improve the system.

The Institute for Safe Medication Practices — publishes best-practice and high-alert-medication guidance for error prevention.

Accredits hospitals and health systems on safety and quality, including National Patient Safety Goals for medication safety.

Setting workflow, staffing, and resource plans to meet patient-care demand safely and efficiently within the pharmacy.

Controls — inventory audits, access limits, surveillance — to detect and prevent theft of controlled substances by staff.

A real-time running count of Schedule II controlled substances to detect discrepancies and diversion.

Technicians perform delegated tasks (data entry, counting) under the pharmacist's supervision; final verification stays with the pharmacist.